Cognition Therapeutics
CGTX
20 hedge funds and large institutions have $8.44M invested in Cognition Therapeutics in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
6.06% more ownership
Funds ownership: 0% → 6.06% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$2.94M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.04M |
| 3 |
AFG
American Financial Group
Cincinnati,
Ohio
|
+$2M |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$975K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$927K |
Top Sellers
CGTX Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q4 2021, worth a combined $8.44M.
Buyers outnumbered sellers: 20 funds opened new CGTX positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $2.94M.
- 20 institutional investors held Cognition Therapeutics (CGTX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $8.44M of Cognition Therapeutics stock for Q4 2021.
- 20 funds opened new Cognition Therapeutics positions in Q4 2021 and 0 closed out, a net change of +20 holders.
- The largest Cognition Therapeutics buyer in Q4 2021 was Prosight Management, an estimated $2.94M added.
Based on aggregated 13F filings for Q4 2021.